Mirum Pharmaceuticals (MIRM) incurred a loss of 30 cents per share in the first quarter of 2025, narrower than the Zacks Consensus Estimate of a loss of 39 cents. The company had reported a loss of 54 cents per share in the year-ago quarter.Revenues in the first quarter totaled $111.6 million, up almost 62$98 million. The top line was driven by strong growth of its marketed products, Livmarli (maralixibat) and recently acquired products, ...